Regen Biologics Inc logo

RGBOQ - Regen Biologics Inc Share Price

$0.011 -0.0  -72.5%

Last Trade - 26/02/21

Sector
Healthcare
Size
Micro Cap
Market Cap £77.2k
Enterprise Value £4.64m
Revenue £1.08m
Position in Universe th / 6715
Bullish
Bearish
Unlock RGBOQ Revenue
Momentum
Relative Strength (%)
1m -10.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -81.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2003 2004 2005 2006 2007 2008 2009E 2010E CAGR / Avg
0.29 0.50 0.57 0.59 0.99 1.37 +36.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2009, ReGenBiologics, Inc. revenues increased 22% to $706K. Net lossapplicable to common stockholders increased from $4.7M to$9.6M. Revenues reflect Sales increase of 24% to $689K.Higher net loss reflects Interest Expense increase from$188K to $1.4M (expense), Research/Development increase of43% to $2.9M (expense), Interest Income decrease of 73% to$12K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RGBOQ Revenue Unlock RGBOQ Revenue

Net Income

RGBOQ Net Income Unlock RGBOQ Revenue

Normalised EPS

RGBOQ Normalised EPS Unlock RGBOQ Revenue

PE Ratio Range

RGBOQ PE Ratio Range Unlock RGBOQ Revenue

Dividend Yield Range

RGBOQ Dividend Yield Range Unlock RGBOQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RGBOQ EPS Forecasts Unlock RGBOQ Revenue
Profile Summary

ReGen Biologics, Inc. (ReGen) is a development stage orthopedic products company that develops, manufactures and markets tissue growth and repair products for United States and global markets. The Company's collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable while others are in various stages of development. ReGen’s first approved product using its collagen matrix technology is the Menaflex collagen meniscus implant device (also known as the CMI), which is marketed for sale in the European Union (EU), Switzerland, Turkey, and the Republic of South Africa, through the Company’s subsidiary, ReGen Biologics AG.

Directors
Last Annual December 31st, 2008
Last Interim June 30th, 2009
Incorporated September 1, 1987
Public Since June 28, 1996
No. of Shareholders: 234
No. of Employees: 16
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 13,151,152
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RGBOQ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RGBOQ
Upcoming Events for RGBOQ
Frequently Asked Questions for Regen Biologics Inc
What is the Regen Biologics Inc share price?

As of 26/02/21, shares in Regen Biologics Inc are trading at $0.011, giving the company a market capitalisation of £77.2k. This share price information is delayed by 15 minutes.

How has the Regen Biologics Inc share price performed this year?

Shares in Regen Biologics Inc are currently trading at $0.011 and the price has moved by 0.450k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Regen Biologics Inc price has moved by 0.320k% over the past year.

What are the analyst and broker recommendations for Regen Biologics Inc?

There are no analysts currently covering Regen Biologics Inc.

When will Regen Biologics Inc next release its financial results?

Regen Biologics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2010-06-30
What is the Regen Biologics Inc dividend yield?

Regen Biologics Inc does not currently pay a dividend.

Does Regen Biologics Inc pay a dividend?

Regen Biologics Inc does not currently pay a dividend.

When does Regen Biologics Inc next pay dividends?

Regen Biologics Inc does not currently pay a dividend.

How do I buy Regen Biologics Inc shares?

To buy shares in Regen Biologics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Regen Biologics Inc?

Shares in Regen Biologics Inc are currently trading at $0.011, giving the company a market capitalisation of £77.2k.

Where are Regen Biologics Inc shares listed? Where are Regen Biologics Inc shares listed?

Here are the trading details for Regen Biologics Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: RGBOQ
What kind of share is Regen Biologics Inc?

We were not able to load our ranking data for Regen Biologics Inc

Is there a Regen Biologics Inc share price forecast 2021?

We were not able to load any forecast data for Regen Biologics Inc.

How can I tell whether the Regen Biologics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regen Biologics Inc. Over the past six months, the relative strength of its shares against the market has been 72.98%. At the current price of $0.011, shares in Regen Biologics Inc are trading at 6.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Regen Biologics Inc PE Ratio?

We were not able to find PE ratio data for Regen Biologics Inc.

Who are the key directors of Regen Biologics Inc?

Regen Biologics Inc's management team is headed by:

Gerald Bisbee - CHM
Alan Baldwin - DRC
J Steadman - DRC
John Dichiara - SVP
William Rodkey - VPR
William Timken - DRC
Jeffrey Chandler - SVP
James Flounlacker - SVP
Dennis O'Dowd - CFO
Who are the major shareholders of Regen Biologics Inc?

Here are the top five shareholders of Regen Biologics Inc based on the size of their shareholding:

Similar to RGBOQ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.